Company intelligence / Profile preview

Alena Pharma

Guatemala City, Guatemalaalenagerber.com ↗

Ownership: Private
Development stage: Other

Overview

Alena Pharma provides a portfolio focused on metabolic health, including advanced GLP‑1 agonists for diabetes and weight management, human insulin, and next-generation anticoagulants. The company leverages regional expertise to deliver innovative treatments across Central and South America. There are no disclosed clinical trial results as the business model centers on commercialization/distribution rather than drug development.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small moleculeBiologicPeptides
Industry: Biotech

Beyond the preview

Go deeper on Alena Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alena Pharma.

Explore the full profile